Randomized Phase II Study of 2nd Line FOLFIRI Versus Modified FOLFIRI With PARP Inhibitor ABT-888 (Veliparib) (NSC-737664) in Metastatic Pancreatic Cancer
Active, no longer recruiting
Phase of Trial: Phase II
Latest Information Update: 19 Jan 2018
At a glance
- Drugs Veliparib (Primary) ; Fluorouracil; Folinic acid; Irinotecan
- Indications Adenocarcinoma; Pancreatic cancer
- Focus Therapeutic Use
- 15 Dec 2017 Status changed from recruiting to active, no longer recruiting.
- 10 Jun 2017 Biomarkers information updated
- 06 Jun 2017 Trial design presented at the 53rd Annual Meeting of the American Society of Clinical Oncology.